Humana is trading lower as the market revisits Medicare Advantage reimbursement risk into the government’s final 2027 Medicare Advantage rate announcement, which is scheduled to be released no later than April 6, 2026. A low preliminary update has kept pressure on the whole Medicare Advantage complex, and Humana—given its heavier Medicare Advantage exposure—has tended to react more sharply than diversified peers. (cms.gov)

The pullback is also occurring against a fragile baseline for expectations after Humana issued notably conservative 2026 guidance and highlighted a substantial Star Ratings-related earnings headwind. In its latest full-year guidance update, Humana pointed to a roughly $3.5 billion net headwind tied to Star Ratings dynamics, reinforcing investor concerns that margin recovery may take multiple years rather than a quick snapback. (policy.humana.com)

Sell-side commentary has stayed cautious, with analyst downgrades and price-target cuts explicitly linking Humana’s valuation debate to Medicare Advantage policy uncertainty and bid strategy risk. Recent downgrades have emphasized that the preliminary 2027 rate update increased perceived policy risk and could complicate a multi-year turnaround, which is keeping dips from attracting durable buyers. (investing.com)

Near-term, traders are focused on any signals about the final 2027 Medicare Advantage rate decision and whether it meaningfully improves versus the preliminary update. Separately, investors are monitoring the trajectory of Humana’s Star Ratings-related pressure and the company’s ability to stabilize profitability into 2027–2028 after resetting expectations for 2026. (cms.gov)